Aurinia Pharmaceuticals Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.14 | -$0.14 | -$0.14 |
Q2 2024 | 1 | $0.01 | $0.01 | $0.01 |
Q3 2024 | 4 | $0.01 | $0.03 | $0.02 |
Q4 2024 | 1 | $0.10 | $0.10 | $0.10 |
Q1 2025 | 2 | $0.09 | $0.09 | $0.09 |
Q2 2025 | 2 | $0.10 | $0.10 | $0.10 |
Q3 2025 | 2 | $0.11 | $0.11 | $0.11 |
Q4 2025 | 2 | $0.14 | $0.14 | $0.14 |
Aurinia Pharmaceuticals Inc. Earnings Date And Information
Aurinia Pharmaceuticals Inc. last posted its earnings results on Thursday, August 1st, 2024. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.01666 by $0.00334. The company had revenue of 57.19 M for the quarter and had revenue of 175.51 M for the year. Aurinia Pharmaceuticals Inc. has generated $-1 earnings per share over the last year ($-0.54 diluted earnings per share) and currently has a price-to-earnings ratio of -23.95. Aurinia Pharmaceuticals Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
Aurinia Pharmaceuticals Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/01/2024 | Q2 2024 | $0.02 | $0.01 | -0.01 | $54.25 M | $57.19 M |
05/02/2024 | Q1 2024 | -$0.17 | -$0.07 | 0.1 | $50.30 M | |
04/29/2024 | Q4 2023 | -$0.19 | $45.10 M | |||
11/02/2023 | Q3 2023 | -$0.17 | -$0.09 | 0.08 | $38.44 M | $54.52 M |
08/03/2023 | Q2 2023 | -$0.20 | -$0.08 | 0.12 | $37.90 M | $41.49 M |
05/04/2023 | Q1 2023 | -$0.24 | -$0.18 | 0.06 | $34.41 M | |
02/28/2023 | Q4 2022 | -$0.26 | -$0.18 | 0.08 | $28.44 M | |
11/03/2022 | Q3 2022 | -$0.18 | -$0.06 | 0.12 | $36.19 M | $55.78 M |
08/04/2022 | Q2 2022 | -$0.22 | -$0.25 | -0.03 | $27.04 M | $28.19 M |
05/10/2022 | Q1 2022 | -$0.26 | -$0.27 | -0.01 | $21.63 M | |
02/28/2022 | Q4 2021 | -$0.26 | -$0.25 | 0.01 | $23.40 M | |
11/03/2021 | Q3 2021 | -$0.31 | -$0.39 | -0.08 | $13.87 M | $14.67 M |
08/05/2021 | Q2 2021 | -$0.35 | -$0.37 | -0.02 | $4.96 M | $6.62 M |
05/06/2021 | Q1 2021 | -$0.35 | -$0.40 | -0.05 | $914,000 | |
02/24/2021 | Q4 2020 | -$0.31 | -$0.06 | 0.25 | $50.03 M | |
09/29/2020 | Q3 2020 | -$0.28 | $43,429 | $29,000 | ||
07/21/2020 | Q2 2020 | -$0.26 | $27,556 | $29,000 | ||
04/20/2020 | Q1 2020 | -$0.20 | -$0.15 | 0.05 | $30,000 | |
02/25/2020 | Q4 2019 | -$0.78 | $29,000 | |||
10/16/2019 | Q3 2019 | -$0.21 | $41,500 | $230,000 |
Aurinia Pharmaceuticals Inc. Earnings: Frequently Asked Questions
-
When is Aurinia Pharmaceuticals Inc.'s earnings date?
Aurinia Pharmaceuticals Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
Did Aurinia Pharmaceuticals Inc. beat their earnings estimates last quarter?
In the previous quarter, Aurinia Pharmaceuticals Inc. (:AUPH) reported $0.02 earnings per share (EPS) to beat the analysts' consensus estimate of $0.01666 by $0.00334.
-
How can I listen to Aurinia Pharmaceuticals Inc.'s earnings conference call?
The conference call for Aurinia Pharmaceuticals Inc.'s latest earnings report can be listened to online.
-
How can I read Aurinia Pharmaceuticals Inc.'s conference call transcript?
The conference call transcript for Aurinia Pharmaceuticals Inc.'s latest earnings report can be read online.
-
How much revenue does Aurinia Pharmaceuticals Inc. generate each year?
Aurinia Pharmaceuticals Inc. (:AUPH) has a recorded annual revenue of $175.51 M.
-
How much profit does Aurinia Pharmaceuticals Inc. generate each year?
Aurinia Pharmaceuticals Inc. (:AUPH) has a recorded net income of $175.51 M. Aurinia Pharmaceuticals Inc. has generated $-0.54 earnings per share over the last four quarters.
-
What is Aurinia Pharmaceuticals Inc.'s price-to-earnings ratio?
Aurinia Pharmaceuticals Inc. (:AUPH) has a price-to-earnings ratio of -23.95 and price/earnings-to-growth ratio is -1.17.